|
Pretzels, Nuts were served and in
total i think we had less than like 14 investors there. Poor showing but
very personal. - - - - - |
|
taxman--my take is IF they dont get
funding they could do a RS so an IND could be in their near future and
discussed I am STUNNED by your take on the IND could she be just being coy on that ? Can it be that maybe its like being readied and she does not want to hint at that ?????????? please explain a bit more if you can DID 118 IN COMBO WITH AN APPROVED DRUG GET DISCUSSED ??? Allen
|
||
|
No. Israel trials she was clear were disappointing. No, She was clear that IND is a tough process and talks have not begun with the FDA yet to start it. We are from drug to market. People wont partner till phase III and we need over 840 million dollars to be a bit more exact . I gotta run. Talk later. |
|
(COMTEX)B: ADVR Announces Investor
Conference Call, Hosted by Company CEO Dr. Elma Hawkins ( PRIMEZONE ) B: ADVR Announces Investor Conference Call, Hosted by Company CEO, Dr. Elma Hawk ns ( PRIMEZONE ) YONKERS, N.Y., Jun 22, 2004 (PRIMEZONE via COMTEX) -- Advanced Viral Research Corp. (OTCBB:ADVR) announced today an investor conference call will be held at 4:00 p.m. Eastern Standard Time on Wednesday, July 21st 2004. Dr. Hawkins will discuss the ASCO presentation and the significance of the data from Israel. The conference call is expected to last one hour and will include a brief question and answer period. ADVR invites all interested parties to participate in the conference call. Participants will be able to access via the Internet or by dialing in to a conference bridge. For those who cannot participate on the live call ADVR will have the call available for replay on the conference line or on www.adviral.com the following day. Instructions for hearing the conference call: Call 1-800-901-5231 in the United States or Canada or Call 1- 617-786-2961 internationally Pin Code: 61291146 Instructions for hearing the conference call replayed: Dates available July 21st-28th Call 1-888-286-8010 in the United States or Canada or Call 1-617-801-6888 Pin Code: 61291146 ADVR's AVR118 represents a biopolymer that possesses novel immunomodulator activity. This peptide-nucleic acid complex, which to date has demonstrated a very favorable safety profile, appears to stimulate the proinflammatory responses required to combat viral infections such as AIDS and human papillomavirus and to dampen aberrant autoimmune-type inflammatory responses, such as occur in patients with rheumatoid arthritis. AVR118 is in clinical trials in Israel for the treatment of cachexia (body wasting) in patients with AIDS. For further information regarding Advanced Viral Research Corp., please visit our website at www.adviral.com. Advanced Viral Research Corp., based in Yonkers, New York, is a biopharmaceutical firm dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for viral and other diseases. Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by the Company. AVR118 (Product R) is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. There is no assurance that the Company will be able to secure the financing necessary to continue and/or complete the clinical trials of AVR118 or satisfy certain other conditions relating to clinical trials including obtaining adequate insurance on terms acceptable to the Company or that if completed, clinical trials performed outside the United States will assist the Company in obtaining FDA or other regulatory approval. . The Company undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise. SOURCE: Advanced Viral Research Corp. By Staff CONTACT: CWR & Partners Ronnie Welch 508/222-4802 (C) 2004 PRIMEZONE, All rights reserved. -0- INDUSTRY KEYWORD: Biotechnology SUBJECT CODE: WEBCAST MEDICAL PHARMACEUTICALS CONFERENCE CALL Calendar of Events *** end of story *** (Voluntary Disclosure: Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy) - - - - - View Replies » |
|
CONFERENCE CALL.....f.i.n.a.l.l.y
-- but it's a month away????? |
|
taxman.....Thanks for the update. I
have a question, could you post your recipe for your gourmet chicken
marinade alfredo!! Ever since you mentioned it, I've been craving chicken!!
Thanks. |
|
taxman- Thanks for the update on
the CEO meeting. Too bad Eli wasn't in pink, it may have suited him! Was there an explanation why an IND application was nowhere on the horizon? Are they waiting for the completion of Israel studies? Is Eli really hopeful that Dicke will come through with funds again and again without seeing any real progress towards getting the drug through the FDA process? Is Eli naive, is Dicke, or does Dicke really have deep, deep pockets? As far as the burn rate goes, it would be nice to look at Elma's and the B.O.D.'s personal expense accounts which are charged to the company, to ensure that they are not living exceedingly well off Dicke's money and the company's limited resources, while the drug and the average shareholder still languish in regulatory purgatory. - - - - - View Replies » |
|
I agree! Maybe Ms. Hawkins better
pay for that DTC report before she gets on a conference call. The worst
thing she could do is not be prepared for this question. It would be very
sad is she doesn't know how many shareholders there are in street name. - - - - - |
|
AT THE 6/21/04 MEET THE CEO MEETING
I ATTENDED THE MEETING YESTERDAY (APPROXIMATELY 15 ATTENDEES TOTAL). MS. HAWKINS WAS AN EXTREMELY ARTICULATE , CREDIBLE & BELIEVABLE INDIVIDUAL WHOSE PRESENTATION WAS QUITE IMPRESSIVE. FROM MY 12 PAGES OF NOTES : AVR 118 (PRODUCT R) : *** REAL BLOCKBUSTER POTENTIAL EXISTS FOR AVR 118 ** IMMUNE MODULATOR ** VERY GOOD SAFETY PROFILE ** WIDE THERAPEUTIC APPLICABILITY * AIDS/CANCER * AUTOIMMUNE DISEASES * INFECTOUS DISEASES *** LARGE POTENTIAL MARKETS WHAT'S NEEDED : *** SYSTEMIC US IND *** GCP CLINICAL TRIALS UNDER IND *** cGMP MANUFACTURING *** NDA WHAT WE HAVE : *** SYSTEMIC US IND *** GCP CLINICAL TRIALS UNDER IND *** cGMP MANUFACTURING *** NDA WE HAVE : *** TOPICAL US IND *** GCP CLINICAL TRIALS WHAT WE HAVE DONE SO FAR : *** REVIEWED ROOM FULL OF DOCUMENTS ** REVIEWED CLINICAL DATA AND PATIENT EXPERIENCES *** SET UP CLNICAL DATA BASES TO ANALYZE DATA FROM 1997-PRESENT *** DATA ENTRY CHOOSING AN INDICATION (POSSESS THE FOLLOWING CHARACTERISTICS) : *** ADDRESS AN IMPORTAMT MEDICAL NEED *** PRIOR EXPERIENCES IN THE INDICATION *** SUFFICIENT PATIENT POPULATION *** SMALL SAMPLE SIZE *** CLINICAL TRIALS OF SHORT DURATION *** CLEAR, OBJECTIVE VALIDATED ENDPOINTS *** ELIGIBLE FOR SPECIAL REGULATORY CONSIDERATIONS *** IDEALLY MINIMAL COMPETITION DEVELOPMENT STRATEGY : *** START WITH LOW-HANGING FRUIT WINNER AT FDA *** EXPAND TO INDICATIONS WITH LARGER MARKET *** HYPOTHETICAL EXAMPLES OF INDICATIONS : ** AIDS ** CANCER ** RHEUMATOID ARTHRITIS ADVR's VALUES : *** EXECUTION *** DOING IT RIGHT *** PERFORMANCE *** QUALITY *** INTEGRITY *** HONESTY *** LEADERSHIP *** COMMITTMENT *** TENACITY *** PASSION (Voluntary Disclosure: Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy) |
|
CORRECTION WHAT WE'LL HAVE : *** SYSTEMIC US IND *** GCP CLINICAL TRIALS UNDER IND *** cGMP MANUFACTURING *** NDA |
|
"Discussion centered on getting and
IND (which is nowhere in the near future according to Elma)" Now in Lauderdale didn't she say end of July or something like that. I recall posting at the time that this was BS. |
|
Hello Folks, Just a quick stop to cut-n-paste the e-mail that I sent to some of you earlier this morning... and then I'm outta here. Notes from the "Meet the CEO" event yesterday in NYC: Combined, Hawkins and her executive staff (Carol Epstein, James Taylor) have 75 years of solid experience in this field, have produced 65 INDa's, and gotten 17 drug approvals. Current O/S 633mm Streamlining expenses Dr H. contract expires at end of 2004 even Epstein & Taylor are not "full-time") No need to raise additional funds in the near future Israeli trials are beneficial to a limited extent, but must do things in the U.S. HPV is not the primary (or current) focus - market doesn't warrant it Cancer trials were stopped in Israel because of $$$ (or lack thereof) only. INDa to FDA is single-most top priority (would not be clear on what indication they would file for). She indicated that she planned to have a major communication outlet to shareholders on a quarterly basis, sometimes via conference call - other times via letter from the CEO (as she did in April). Intends to actively pursue presentation opportunities at appropriate conferences and looking to become better known through media campaign. PR's will NOT be used as a regular vehicle for shareholder communication - but only to announce "material" events. However, they are planning on a new or redesigned web-site that will provide for better dissemination of information, etc... The following is my personal comments/impressions: I think we have the right person to steer this ship into port - seems professional, self-assured (but not arrogant), organized, well-spoken and hard-driven. Though couched in diplomacy, it seemed apparent that she felt that the company had no real direction under previous leadership (Dr. H). Sort of like Shalom KNEW what he had in "R" - but did NOT KNOW how to go about the business of getting it to market. I'll be very surprised if he is employed or contracted in any way whatsoever after Dec 31, 2004. The disappointment over the discontinuation of the Cancer tumor trials in Israel will not be for much longer - suspect that we'll hear more about that by year-end. Those that feel that a PR should be issued every time something of even remote interest occurs will continue to be disappointed - PR's will only be used for announcements of material events My only disappointment is that they seem to be satisfied with the current Investor Relations relationship. They seem to me much more attuned to Public Relations (media, etc) than they are to investors (you and me). Anyway, folks, there you have it: my report and my commentary. |
|
"Dont believe any application for
this drug aside from caxchia and the Israel study was not given glowing
reviews by Emma" ----------------------------------------------- Tax - and this in contrast to the early-on glowing description of this drug that made many buy in:: an all purpose anti-viral and immunomodulator that is capable of MANY indications. My take on the company's prospects:: POOR My take on my evolving consideration of AVR118's medical/scientific worth: Equivocal. It's one thing when you feel management is a problem, but if one begins to doubt the worthiness of the drug itself...watch out! There continues to be something wrong with this picture...and any prospect of a sudden turn-around seems out of the question. Either bankruptcy or a reverse split up the road. It now seems that partnership is a totally remote possibility, especially when the CEO sees no tremendously outstanding potential at this time. (Voluntary Disclosure: Position- No Position; ST Rating- Strong Sell; LT Rating- Strong Sell) |
|
My ONE question to you is... ...was there anything in her presentation that we haven't heard over and over again since 1995?? (Voluntary Disclosure: ST Rating- Strong Sell; LT Rating- Strong Sell) |
|
have any of the pumpsters opinion
of Dr H changed at all? i seem to be remember the initial arguments here
starting over "Hirschman is God" on one side, and "Hirschman couldn't run a
7/11 deli display" on the other. was the good ole Dr lining his pockets
while the company made almost zero headway? (as many have suggested for
quite some time). certainly Rarboston, kev, Bernie, to name a few. meanwhile
the gator, mega, britt, foxy-pump Hirschman crew, never seemed to
understand. will they admit they were very very wrong? i don't think so. no,
they were-are busy pumping advr, blaming mms, bashers, etc., while posting
stupidity that has ranged over the years from west nile virus (and a hundred
other diseases), fast-track, to partners, to China. what a bunch of jamooks.
those posters, imo, have damaged the company as badly as Hirschman with
their silly hype-excuses. gooooooo advr (Voluntary Disclosure: Position- Long) |
|
spark, it is not a matter of
"knocking" the company. Those of us that were not at the meeting just want
to know what was said. The issue of when we will file and INDA IS crucial.
Elma was said to have indicated June/July when in Lauderdale. You are
evading an answer. I know damn well she was asked that question- when will
we file an INDA. Someone is spinning the truth, that's for sure. Let me tell
you something and you can mark this down. The Market isn't going to give a
chit about the "direction" we are moving in. The Market wants results- like
an INDA for example. Without that kind of result to sustain the PPS, we will
see .05 again IMO. |
|
SPARKR BOARD: Look anyone at the meeting will agree that Elma said talks with the FDA have not began yet and that she also said the INDA is not in the near future. Personally, I would define July of 04 as in the near future. The Israel trials.. How long were they? Did she mention how its difficult to measure weight gain/loss in such a time frame. Guys its June. Yesterday Elma said talks have not begun with FDA and no tests are going on in the US. Yes, she has connections. I am stating my opinion of what happened yesterday, but there were no facts stated. It was opinion. If she is so damm driven. Dump her salary and make her work for the pps. We are going broke. We need a partner or we will go through a r/s and we will all tank. This is hanging on a thread. I would wait till the next market swing to anything better than .18 and dump. I cant believe that after hearing what was said yesterday someone would go off and tell the board July 2004 is still an option for an INDA. Seriously. And Hpv ALONG WITH OTHER OPTIONS would require different tests trials, that venue is not even worth talking about.
|
||
|
Not to mention. She wants to save
PR'S for meaningful hard hitting news. Interesting. No trials in the US, no
backing to distribute in China but yet we get pr's about that. Why were
these pr's issued. Be honest with yourself the money is not there to pursue
the HPV option and yet we get a pr about that. |
|
ADVR's VALUES : *** EXECUTION *** DOING IT RIGHT *** PERFORMANCE *** QUALITY *** INTEGRITY *** HONESTY *** LEADERSHIP *** COMMITTMENT *** TENACITY *** PASSION I THINK I'M GOING TO PROJECTILE VOMIT |
*******************************
|
ADVR's Values (as demonstrated to
Shareholders to date) ***Procrastination ***Doing it Wrong ***Silence on Issues ***Lack of Performance ***Unkept Promises ***Spending Money ***Wasting Money ***Touting AVR118 for everything under the sun ***Constantly Changing Direction Mid-Stream ***Holding repeated "Meet our Charming New CEO" sessions ***Trite CEO Soundbytes (on would-be company values) ***A "Who cares diddlysquat about our investors?" philosophy. - - - - - |
*************************************
|
"I don't knock a company that I am
heavily invested in; if I did I would sell all my shares first, and then
start knocking . Isn't that the normal thing to do?" Yes, SPARKR, I agree completely and this has always been my thinking. And, yes, I do believe that is the normal thing to do if dealing with "normals" here. Thank you so very much for your explicit report on yesterday's meeting in Yonkers, and also for your several follow-up posts as well. Good job! Great work! Much appreciated. Luv |
|
Once again we have had a “Meet the
CEO session” Allowing us to feed upon our ADVR obsession. The CEO, pretty in pink, is ready with a smile To charm gentlemanly investors; indeed to beguile. No IND as yet- that fact alas is true If AVR118’s no good on warts, we’ll sell it as Super Glue. We’re working hard sorting data, can’t you all just see? Meanwhile munch some pretzels- they’re absolutely free! The PPS of company stock admittedly is low But wait! Good news lies ahead- the drug works in vertigo! “I’ve connections” states the CEO,“I’ll put them to good use The Dickes pump more money in, what have they got to lose? I’ve done great in former jobs, you’ve a great CEO at last And yes,of course, Hirschman’s to blame, for all things in the past. Our cGMP production makes for very pretty vials- We ship them out to Israel, and then cancel the trials. For HPV in Phase I trials, our drug worked rather swell But we’ll shift gears- next IND’s for arthritis as well. “Tenacity” and “Passion” are my soundbytes for today “Leadership and “Commitment” too- lets’ all shout “Hooray!” The stock’s price is indeed low, but what’s the frickin’ fuss? Speaking on behalf of the B.O.D., “The company’s been good to us.” - - - - - |
|
"She also stated that : "Getting a drug approved is a process" ; "Just pushing a drug through the FDA is NOT possible"; "Having 5 or 10 or 100 case reports is not accepted by the FDA ; "There is a sequence of events that need to be followed in a certain order" ." |
|
Another reason to call it worthless
- when you look at the big picture. By the way, have you seen mbengineer lately and gotten his take on Emma's report? Or the unbelievable results from Israel that everyone has been waiting with bated breath for?? (Voluntary Disclosure: ST Rating- Strong Sell; LT Rating- Strong Sell) |
|
Bernie & Mind, what the heck has
ADVR been doing in the past almost 5 years I've been invested is way beyond
my comprehension. I am so disgusted with the run-around approach with past
and present management I could literally scream. Why in the heck did we go
to Israel, when we could have gotten (I am sure) an INDA for systemic here
in the U.S. This whole ADVR set-up is totally ridiculous. Does anyone in the company want this drug to succeed or not??? Or, as has been stated by my friend, rarboston, is this whole thing just been a scam and management is just milking the shareholders dry (or words to that effect). For anyone of the "pumpers" here to even suggest the "new" management is any different than the old is totally beyond reason (or just plain NUTS). The PPS stands where it is (obviously, the price cannot fall below $.10 until the Dickie deal is over and done with) and the investment community is as disgusted as SOME of us LONGS and truth-tellers! I'm really tired of making excuses for this sad excuse of an investment. I have a feeling I will never make any money here, but when I entered into this investment it was "free money" and was just a gamble, until I became totally involved and intrigued in what seemed to be something indeed worthwhile, after all. Obviously, I was wrong again and two wrongs don't make it right. If, by some MIRACLE, the stock does get to $.55-$.60, I WILL INDEED SELL, take my original investment and buy or invest in something much more valuable than a "belief or a dream"! Good night, my little chickadees (you know who you are)!!!...LOL Sue - - - - - |
|
rick-problem here is $$$$$$$$$ we will never know if this is a super drug for anything-- I think they have a real situation on there hands here its NOT insurmountable--its Negotiable |
|
I dont think that will happen Barry
.05 I wonder how many are out there that would help ADVR move forward-I bet there are other Dickies YOU GOT TO LOOK AT THE BRIGHT SIDE MUCH OF THE COMPANIES PROBLEMS WERE BEGUN LONG AGO THIS CEO CAME IN KNOWING THAT I THINK SHE CAN DO IT AND GET THE $$$$$$$$ TO GET INTO A US TRIAL I AM COUNTING ON IT FROM THERE 118 HAS TO STAND ON ITS OWN AND PROVE OUT I support her Allen |
|
Hey, Sue, stop picking on advr. I'm losing my shirt of this stock too. It's tanking because I'm in at .13. Every stock I buy, somehow always manages to tank and rebound after it tanks. The mm's are always testing me. take care. |
|
remember, there will be "surprises"
in store for us from asco. i was surprised lol. have you noticed any
similarity in character between folks employed by the company and some of
the more "supportive" true longs here? engineer seems to be a combination of
both. they continue to listen to each other, pat each other on the back,
call us bashers, predict partnerships-fast track-china deals, and ignore the
obvious. IND application june or july but advr hadn't decided the
indication? even if it will be systemic? applications must be laying around
all over the place (i sense a lie in there somewhere). i knew we were in
trouble when i saw those faxed raging bull posts on the desk in the bahamas.
advr is doing what they have always done imo, putting all their eggs in the
"hope for fast track" basket with no alternate plan. no application by the
end of July will be another failure. even if they do it, no awarding of any
type of expedited testing will be yet another failure. my prediction is
failure, followed by a reverse split. they have painted them selves into a
corner, again. goooooo advr go (Voluntary Disclosure: Position- Long) |